Dual αvβ6 and αvβ1 Integrin Inhibition Reduces Lung Collagen Deposition in Idiopathic Pulmonary Fibrosis: Insights from a Phase 2 Clinical Trial

Highlight

This phase 2, double-blind, placebo-controlled trial evaluated the effects of bexotegrast, an oral dual inhibitor of αvβ6 and αvβ1 integrins, on type I collagen deposition in patients with idiopathic pulmonary fibrosis (IPF). Utilizing 68Ga-CBP8 PET imaging, the study demonstrated a reduction in active collagen accumulation with bexotegrast compared to placebo over 12 weeks. Additional assessments suggested improved lung microvascular function and favorable changes in pulmonary function and symptomatology.

Study Background